Mild Cognitive Impairment — Evaluation of an Intervention for Living With Mild Cognitive Impairment
Citation(s)
Blieszner R, Roberto KA Care partner responses to the onset of mild cognitive impairment. Gerontologist. 2010 Feb;50(1):11-22. doi: 10.1093/geront/gnp068. Epub 2009 Jun 2.
Cotelli M, Manenti R, Zanetti O, Miniussi C Non-pharmacological intervention for memory decline. Front Hum Neurosci. 2012 Mar 9;6:46. doi: 10.3389/fnhum.2012.00046. eCollection 2012.
Petersen RC Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004 Sep;256(3):183-94. Review.
Savla J, Roberto KA, Blieszner R, Cox M, Gwazdauskas F Effects of daily stressors on the psychological and biological well-being of spouses of persons with mild cognitive impairment. J Gerontol B Psychol Sci Soc Sci. 2011 Nov;66(6):653-64. doi: 10.1093/geronb/gbr041. Epub 2011 Jul 6.
Simon SS, Yokomizo JE, Bottino CM Cognitive intervention in amnestic Mild Cognitive Impairment: a systematic review. Neurosci Biobehav Rev. 2012 Apr;36(4):1163-78. doi: 10.1016/j.neubiorev.2012.01.007. Epub 2012 Feb 1. Review.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
